ActiveMSers Forums  

Go Back   ActiveMSers Forums > ActiveMSers.org Forums > Dave's SCT Journey

Reply
 
Thread Tools Display Modes
  #1  
Old 06-24-2017, 06:48 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
 
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,056
Default Is HSCT safe and effective in teens with MS? STUDY

Hematopoietic stem cell transplantation for children with multiple sclerosis and neuromyelitis optica: Long-term outcomes and late effects

K. Kirgizov, R. Bembeeva, E. Volkova, E. Pristanskova, N. Sidorova, V. Konstantinova, O. Blagonravova, S. Piliya, E. Skorobogatova, N. Zavadenko, A. Rumyantsev

*Show more
https://doi.org/10.1016/j.ejpn.2017.04.674
Get rights and content

Objective: To estimate long-term outcomes and late effects at children underwent Autologous HSCT for multiple sclerosis (MS) and Allogenic HSCT for neuromyelitis optica (NMO).

Methods: Fifteen pts. included (MS 12, NMO 3). MS: female 9, male n*=*3; NMO: all females. MS median age 16,8**1,6 y.o., median length of MS prior HSCT 17,5**3,4 months, debut age: 13,4**1,5 y.o. (415 y.o.). Median EDSS 6,16**0,2. NMO pts. median age 12,7**1,4 y.o., median length of NMO prior HSCT 19,2**4,1 months, debut age: 10,2**0,4 y.o. (911 y.o.). All patients had severe*refractory disease treated with different immunosuppression, but still have inflammation signs. MS patients received Cyclophosphamide and ATGAM based chemotherapy and NMO patients received Treosulfan, Fludarabine, Rituximab and ATGAM. Late effects estimation due to developed protocol for late effects estimation (somatic and neurocognitive status).

Results: EDSS improved at MS patients fast on 3,1**0,3 during first 60 days. Median follow-up 40,7**2,4 months (1076 months). Two MS patients relapsed (clinical and MRI). No severe complications registered. NMO patients stopped the progression and improved neurologically (clinical and MRI). One pt. with NMO died due to refractory ADV-infection, two patients did not have any severe toxic episodes. Median follow-up 23**4,7 months (160 months). MS patients late effects: cardio-vascular 5 pts., endocrine* 3 pts (all females). NMO patients late effects: cardio-vascular 2 pts., late immune reconstitution 1 pt. One NMO patient experienced skin cGVHD. All patients had deficit in neurocognitive*sphere and received special rehabilitation.

Conclusion: HSCT is successful approach for refractory pediatric MS and NMO treatment. In-time HSCT can significantly improve the outcome. Most of the patients remain in remission during the long time of follow-up. Late effects can be found in these patients, so it's important to find it and give adequate rehabilitation.
__________________
Dave Bexfield
ActiveMSers
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -4. The time now is 08:19 PM.


Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2017, Jelsoft Enterprises Ltd.
ActiveMSers